Invitation to presentation of Orexo´s Full Year Report 2023

Uppsala, Sweden – January 30, 2024 – As previously communicated Orexo will announce the Full Year Report 2023, focusing on the development in the fourth quarter, on February 8, at 8 am CET.

The same day at 2 pm, analysts, investors, and media are invited to attend a presentation where Nikolaj Sørensen, CEO, and Fredrik Järrsten, CFO, will present the latest development and host a Q&A.

To attend via teleconference where you can ask questions verbally use this link: 
https://conference.financialhearings.com/teleconference/?id=2001504

When registered you will be provided phone numbers and a conference ID to access the conference.

To attend via webcast:
https://ir.financialhearings.com/orexo-q4-2023

Prior to the event the presentation material will be available on the website under Investors/Reports, Presentations.

For further information, please contact:

Orexo AB (publ.)
Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
Email: ir@orexo.com

About Orexo
Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2022 amounted to SEK 624 million, and the number of employees to 126. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.

For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on X (former Twitter), LinkedIn, and YouTube.